RELIEF THERAPEUTICS Holding SA announced the appointments of Jack Weinstein, MBA, to chief executive officer, effective immediately. Jack Weinstein, MBA, joined Relief in October 2020 as its U.S.-based chief financial officer and treasurer. He brings over 40 years of wide-ranging executive management expertise, including as a chief financial officer, investment banker and consultant in the biopharmaceutical industry.

He has extensive experience in finance and healthcare investment banking, corporate and business development, as well as U.S. Food & Drug Administration regulatory and intellectual property strategies. Mr. Weinstein has successfully completed a variety of corporate finance transactions, including public and private financings, as well as mergers and acquisitions. Before joining Relief, he served as managing director and head of healthcare investment banking at Avalon Group Ltd., an independent New York-based boutique investment bank.

Prior to that, Mr. Weinstein was chief financial officer, treasurer and vice president of business development at Catalyst Pharmaceuticals Inc., a biopharmaceutical company developing prescription pharmaceutical products, where he led the company's public listing on Nasdaq. Mr. Weinstein also previously served as president and founder of The Sterlington Group Inc., a consulting firm providing strategic, business development, regulatory and CFO consulting services, including mergers and acquisitions advisory and raising equity and debt for middle-market companies. He has also gained experience at several other investment banking and consulting firms. Mr. Weinstein earned a master of business administration from the Harvard Business School and graduated with a BM degree from the University of Miami, magna cum laude .

Mr. Weinstein holds FINRA Series 79 (Investment Banking Representative Exam) and 63 (Uniform Securities State Law Examination) Licenses.